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Many transcription factors, particularly those involved in the con-
trol of cell growth, are unstable proteins destroyed by ubiquitin-
mediated proteolysis. In a previous study of sequences targeting
the transcription factor Myc for destruction, we observed that the
region in Myc signaling ubiquitin-mediated proteolysis overlaps
closely with the region in Myc that activates transcription. Here, we
present evidence that the overlap of these two activities is not
unique to Myc, but reflects a more general phenomenon. We show
that a similar overlap of activation domains and destruction ele-
ments occurs in other unstable transcription factors and report a
close correlation between the ability of an acidic activation domain
to activate transcription and to signal proteolysis. We also show
that destruction elements from yeast cyclins, when tethered to a
DNA-binding domain, activate transcription. The intimate overlap
of activation domains and destruction elements reveals an unex-
pected convergence of two very different processes and suggests
that transcription factors may be destroyed because of their ability
to activate transcription.
Cells exploit a variety of mechanisms to keep the function oftranscriptional activators tightly in check. Processes that
limit the activity, location, and abundance of transcription
factors play an important role in regulating gene expression and
maintaining cellular homeostasis. One prominent mechanism
regulating transcription factor function is proteolysis; the rapid
and controlled destruction of transcription factors like Myc (1),
Jun (2), p53 (3), and E2F-1 (4) keeps the intracellular levels of
these proteins low and responsive to environmental stimuli.
Although several proteolytic processes have been implicated in
transcription factor destruction—such as cleavage by calpains
(5) and lysosomal proteases (6)—the most widespread pathway
of transcription factor turnover is ubiquitin (Ub)-mediated
proteolysis.
Ub-mediated proteolysis is a process in which proteins to be
destroyed are tagged by linkage to a small, highly conserved
protein known as Ub (7). Covalent attachment of Ub to proteins
signals their destruction by the 26S proteasome, a large complex
with multiple proteolytic activities (8). Ub-mediated proteolysis
features in many cellular events, including the cell cycle, antigen
presentation, and DNA repair (7). The versatility of this system
stems from both its diversity and its specificity. Because cells
possess a diverse collection of ubiquitylating enzymes, Ub-
mediated proteolysis targets a wide range of proteins for de-
struction. Because destruction by the proteasome generally
depends on prior substrate ubiquitylation, Ub-mediated prote-
olysis destroys its substrates with extreme precision.
Central to the control of Ub-mediated proteolysis, therefore,
are the interactions between target proteins and components of
the ubiquitylation machinery. Despite the importance of this
process, however, the mechanisms governing substrate recogni-
tion in this pathway are poorly understood. It is known that
substrate recognition is usually mediated by the action of
Ub-protein ligases, and that substrate proteins contain an ele-
ment—sometimes referred to as a degron (7)—that signals
ubiquitylation. With the notable exceptions of N-end rule de-
grons (9) and cyclin destruction boxes (10), however, most
degrons are poorly defined and are characterized, at best, by a
preponderance of certain types of amino acids (e.g., PEST
sequences; ref. 11). The crude characterization of degrons has
hampered the understanding of how proteins are targeted for
Ub-mediated destruction.
During a previous analysis of sequences targeting the tran-
scription factor Myc for destruction, we found that the Myc
degron overlaps closely with the Myc transcriptional activation
domain (TAD; ref. 1). The Myc TAD and degron both reside
within the first 143 aa of Myc, they both are diffuse elements—
made up of a number of smaller subelements—and they both are
able to function in yeast as well as in mammalian cells. Moreover,
the ability of these sequences to activate transcription accurately
reflects their ability to signal proteolysis. Based on these simi-
larities, we concluded that it is the Myc TAD per se that signals
Myc destruction.
Here, we have asked whether the overlap of transcriptional
activation and protein destruction elements is peculiar to Myc or
reflects a more general phenomenon. We report that this overlap
is observed in other unstable transcription factors, that an
intimate relationship can exist between these two activities, and
that, just as activation domains can signal proteolysis, so too can
degrons activate transcription. The surprising duality of these
sequences implies a functional link between transcription and
Ub-mediated proteolysis, and suggests that activation domain-
directed protein destruction is a common mechanism regulating
transcription factor stability.
Materials and Methods
Plasmid DNA Manipulations. Mammalian expression constructs
encoding GAL4-fusion activators were created by subcloning
activation domain-encoding sequences into the XbaI and BamHI
sites of pCG-GAL(HA) (1). The relevant details for activation
domains used are: (i) CCAAT-box transcription factor (CTF),
one copy of the proline-rich CTF TAD (residues 399–499) (12);
(ii) Q18, four copies of an 18-aa glutamine-rich TAD from Oct-2
(13); (iii) Q19, four copies of a 19-aa TAD from Oct-1 (13); (v)
Sp1, one copy of the glutamine-rich Sp1 B domain (residues
263–391; ref. 14); E2F, one copy of the acidic E2F-1 TAD
(residues 389–437; ref. 15); (vi) VP16, one copy of the acidic
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VP16 TAD (residues 413–490; ref. 16); and (vii) VN8, one, two,
three, or six copies of a wild-type 8-aa sequence from the VP16
TAD, DFDLDMLG, or three copies of the mutant sequence
DADADMLG (M. Tanaka, Tokai University; ref. 17). Yeast
expression constructs encoding hemagglutinin (HA)-tagged
GAL4-fusion activators were created by excising XhoIyBamHI
fragments from the relevant pCG-GAL(HA) constructs and
transferring these into the XhoI and BamHI sites of pGBT9
(CLONTECH). To construct pGBT9–Cln2 and pGBT9–Cln3,
sequences encoding the Cln2 PEST (residues 368–545; ref. 18)
and Cln3 PEST (residues 380–580; ref. 19) regions, respectively,
were first cloned into the XbaIyBamHI sites of pCG-GAL(HA).
These constructs then were cleaved with XhoI and BamHI, and
the appropriate fragments were cloned into the XhoI and BamHI
sites of pGBT9.
Human Cell Experiments. All human cell experiments were per-
formed by transient transfection of human HeLa cells using
calcium phosphate coprecipitation (1). To determine steady-
state protein levels, 5 3 105 HeLa cells, growing on a 6-cm dish,
were transfected with 400 ng of the indicated pCG-GAL(HA)
expression construct, along with 10 mg of pUC119 carrier DNA.
Twenty hours after transfection, cells were treated with protea-
some inhibitors—either 25 mM proteasome inhibitor 1 (PS1;
Calbiochem) or 25 mM N-acetyl-Leu-Leu-norleucinal (LLnL;
Calbiochem), as indicated—or an equivalent amount of DMSO.
Twelve hours later, cells were harvested (1), and the steady-state
level of GAL4-fusion proteins was determined by immunoblot-
ting, probing with the anti-HA antibody 12CA5 (C. Bautista,
Cold Spring Harbor Laboratory). Protein stability was deter-
mined by pulse–chase analysis using the method of Hofmann
et al. (20) as previously modified (1). Transcriptional activation
was determined by transfecting 10-cm dishes of HeLa cells with:
(i) 1 mg of the reporter plasmid p4xGal.c-fos.TAT.luc, (ii) 1 mg
of the b-galactosidase expression plasmid pSVbgal, (iii) 400 ng
of the appropriate pCG–GAL(HA) expression plasmid, and (iv)
18 mg pUC119, as described (1). Forty hours later, cells were
harvested and luciferase and b-galactosidase activities were
determined as described. Protein ubiquitylation was measured
by using the polyhistidine-tagged Ub method of Treier et al. (2).
Yeast Experiments. Saccharomyces cerevisiae yeast strain HF7c
(21) (G. Hannon, Cold Spring Harbor Laboratory) carries two
integrated, GAL4-dependent, reporter constructs, one driving
synthesis of HIS3p, the other driving synthesis of b-galactosi-
dase: GAL4 activity thus can be measured as both growth in the
presence of 3-amino-triazole (3AT), a competitive inhibitor of
the His3 product, and as b-galactosidase activity. HF7c cells
were transformed with the indicated pGBT9 constructs and
transformants were selected by growth on complete synthetic
media (CSM) lacking tryptophan. Growth in the presence of
3AT was scored on CSM plates lacking tryptophan and histidine
and including 2 mM 3AT (Sigma). b-galactosidase activity was
measured in solution according to the protocol of Herskowitz
(www.sacs.ucsf.eduyhomeyHerskowitzLabyprotocolsybgal2.
html).
Results and Discussion
Activation Domains and Degrons Overlap in Many Unstable Transcrip-
tion Factors. Our previous analysis of Myc destruction revealed
that the Myc degron overlaps closely with the Myc TAD (1). As
a first approach to understanding the significance of this overlap,
we asked whether a similar overlap occurs in other transcription
factors destroyed by Ub-mediated proteolysis. We reviewed the
literature and identified 10 transcription factors in which both
TADs and degrons have been mapped; we then compared the
positions of the TADs and degrons within these factors. The
results of this comparison are presented in Table 1. In two
instances—b-catenin and Myb—TADs and degrons are clearly
separate. In eight instances, however—E2F-1, Fos, GCN4, HIF-
1a, Jun, Myc, p53, and Rel—TADs and degrons overlap. The
overlap of TADs and degrons in these proteins is extensive, and
striking considering that, for each protein, different groups have
mapped the different elements by using different strategies. The
frequency with which these two types of elements overlap
suggests that, rather than being peculiar to Myc, the colocaliza-
tion of activation domains and degrons is common among
unstable transcriptional factors.
Activation Domain Function Is Not Sufficient to Direct Protein Insta-
bility. To account for the widespread overlap of TADs and
degrons we observed, we considered two explanations. First, we
considered that any sequence that activates transcription also
signals proteolysis. Although the separate TADs and degrons of
b-catenin and Myb (Table 1) argue against this possibility, it is
conceivable that TADs and degrons do overlap in these proteins,
but that this overlap has not yet been reported. Second, we
considered that degron function occurs in a subset of activation
domains, and that there is some unique aspect of the E2F-1, Fos,
GCN4, HIF-1a, Jun, Myc, p53, and Rel TADs that gives them
degron function. To distinguish between these two possibilities,
and to see whether we could identify other sequences with
TADydegron function, we surveyed several activation domains
for their ability to signal protein instability. Results of this
analysis are presented in Fig. 1.
We selected a number of activation domains, classified as
either proline-rich (CTF), glutamine-rich (Q18; Q19; Sp1), or
acidic (VP16; E2F-1; Myc), and expressed these domains in
human HeLa cells as fusions to the DNA-binding domain (DBD)
of the yeast transcription factor GAL4. We first examined the
steady-state levels of these proteins, either in the absence or
presence of PS1, an inhibitor of the proteasome, as shown in Fig.
1A. In the absence of proteasome inhibitor (2PS1), the GAL4
DBD alone (D; lane 2), as well as GAL4 fused to the CTF, Q18,
Q19, and Sp1 activation domains (lanes 3–6), accumulated to
levels readily detected by immunoblotting. GAL4-fused to the
Table 1. Relationship of TADs and degrons in unstable
transcription factors
Factor Position of TAD* Position of degron* References†
E2F-1 368–437 418–437 (15)
(4)
Fos 308–380 359–380 (22)
(23)
GCN4 87–152 99–106 (24)
(25)
HIF-1a 531–575 401–603 (26)
(27)
Jun 5–196 1–67 (28)
(2)
Myc 1–146 1–143 (29)
(1)
p53 1–73 1–40 (30)
(31)
Rel 416–521 427–480 (32)
(33)
b-catenin 695–781 32–37 (34)
(35)
Myb 198–356 549–536 (36)
(37)
*In cases where two or more TADs or degrons have been mapped within a
single transcription factor, only the overlapping TADs and degrons are listed.
†References are listed for the activation domain first, degron second.
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VP16, E2F, and Myc TADs, in contrast, did not accumulate to
detectable levels (lanes 7–9), consistent with the possibility that
these TADs destabilize the GAL4 DBD. This possibility was
further reinforced by the observation that treatment of trans-
fected cells with PS1 (1PS1) caused the GAL4–VP16, –E2F,
and –Myc activators to accumulate to detectable levels (lanes
7–9), without appreciably altering expression of the other
GAL4-fusion proteins (lanes 2–6).
To ask whether these differences in protein accumulation
reflect differences in protein stability, we performed pulse–
chase analysis, a representative sample of which is shown in Fig.
1B. Consistent with our previous observations, the GAL4 DBD
alone (D) had a half-life of approximately 90 min. Fusion of
GAL4 DBD to the CTF activation domain (CTF), or the Q18,
Q19, and Sp1 activation domains (data not shown) did not
decrease GAL4 DBD stability. Fusion of GAL4 to the VP16
activation domain, in contrast, resulted in a significant decrease
in protein stability, yielding a protein with a half-life of around
60 min. Consistent with previous reports (4), the E2F activation
domain also destabilized the GAL4 DBD. Both GAL4-VP16
and GAL4-E2F were stabilized by treatment with PS1 (data not
shown), demonstrating that proteasome function is required for
the rapid turnover of these proteins.
Taken together, these data demonstrate that an activation
domain per se does not signal proteolysis. Out of the activation
domains we compared, only the VP16, E2F-1, and Myc TADs
could signal protein destruction, suggesting there is something
unique to these domains that gives them degron function. When
we compared the sequences of these activation domains with the
other TADydegrons listed in Table 1, we were unable to identify
any convincing regions of sequence homology that would dis-
tinguish a TAD with degron function from an activation domain
without. We do note, however, that most of the TADydegrons
listed in Table 1, together with the VP16 activation domain, are
characterized by a preponderance of acidic amino acid residues.
We therefore conclude that degron function is restricted to a
subset of TADs enriched in acidic residues, and that, like TAD
function itself, the degron function of these elements cannot be
related to a clearly identifiable sequence motif.
Close Correlation Between Activation Domain and Degron Function in
a Family of Synthetic Transcriptional Activators. Our previous anal-
ysis of Myc (1) revealed a close correlation between activation
domain and degron function. To determine whether this is true
in other cases, we asked whether a series of TADs, derived by
reiteration of an 8-aa sequence (DFDLDMLG; referred to as
VN8) from the VP16 TAD (17), also could signal proteolysis. We
chose these TADs because they are well defined and potent, and
because their transcriptional potency can be varied predictably
by changing their copy number and sequence. Fig. 2 shows the
structure of GAL4–VN8 activators, together with their relative
transcriptional activities in human cells. Each activator was
constructed by fusing the GAL4 DBD to either one, two, three,
or six tandem copies of VN8, or three copies of a mutant VN8
sequence—DADADMLG (17). Transcriptional activity then
was measured by the ability of each activator to drive expression
of a GAL4-binding site-containing reporter in human HeLa
cells. Consistent with their activities in yeast (17), increasing the
copy number of VN8 modules increased transcriptional potency.
One copy of VN8 fused to the GAL4 DBD activated transcrip-
tion 2-fold more than the GAL4 DBD alone, two copies
activated transcription more than 100-fold, and three and six
copies resulted in approximately 1,000- and 2,000-fold increases
in transcriptional activation, respectively. As in yeast (17), the
mutant VN8 module was much less potent (compare the activity
of the 33 and 33M activators).
To address whether these TADs also function as degrons, we
first compared the steady-state levels of the different GAL4–
Fig. 1. The VP16 activation domain, but not other domains that activate
transcription, confers protein instability. (A) Steady-state levels of GAL4-
fusion activators. Human HeLa cells were transiently transfected with expres-
sion constructs encoding the indicated GAL4–fusion activators (lanes 2–9) or
with pUC119 carrier DNA (lane 1). After transfection, cells were treated with
either DMSO solvent (2PS1) or PS1 (1PS1). Cells then were harvested, and
equal volumes of total cell lysates were resolved by SDSyPAGE. GAL4-fusion
proteins were detected by immunoblotting. (B) Stability of GAL4-fusion acti-
vators. The indicated GAL4-fusion proteins were transiently expressed in HeLa
cells and pulse–chase analysis was performed as described (1). Labeled GAL4–
fusion proteins were recovered by denaturing immunoprecipitation, and
visualized by SDSyPAGE followed by autoradiography.
Fig. 2. Tandem reiteration of the VN8 module generates transcriptional
activators of widely differing potencies. (A) Structure of synthetic activators
used in this study. Each activator carried the GAL4 DBD fused to 13, 23, 33,
or 63 copies of the wild-type VN8 sequence, or three copies of mutant VN8
sequence (33M). (B) Relative transcriptional potency of each activator. GAL4-
fusion proteins were assayed for transcriptional activation in human HeLa cells
as described in Materials and Methods. Relative transcriptional activity is
shown on a logarithmic scale, setting the transcriptional activity of the GAL4
DBD alone (D) at 1.
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VN8 fusion proteins in the absence (2LLnL) or presence
(1LLnL) of the proteasome inhibitor LLnL. The results of these
studies are shown in Fig. 3A. The GAL4 DBD alone accumu-
lated to the highest level (lane 1). Addition of one copy of VN8
reduced protein accumulation by approximately 50% (lane 2),
whereas addition of two (lane 3), three (lane 4), or six (lane 5)
copies of VN8 reduced protein accumulation to beneath detect-
able levels. Strikingly, however, the mutant 33VN8 activator
(lane 6) did accumulate to low, but detectable, levels under these
conditions. Treatment of transfected cells with the proteasome
inhibitor LLnL significantly altered the accumulation of these
proteins; indeed, in the presence of LLnL (1LLnL), all GAL4-
fusion proteins accumulated to comparable levels (compare
lanes 1–6). Together, these data demonstrate: (i) that the
accumulation of these transcriptional activators in human cells is
inversely related to their transcriptional potency, and (ii) that a
functioning proteasome is required for the low steady-state
levels of the potent transcriptional activators.
We next used pulse–chase analysis to measure the stability of
the GAL4-VN8 fusion proteins, as shown in Fig. 3B. As before,
the GAL4 DBD had a half-life of around 100 min. Addition of
one VN8 module reduced the protein half-life to around 60 min,
whereas addition of three and six copies of VN8 further reduced
the protein half-life to 15 and 17 min, respectively. The mutant
33 activation domain, in contrast, had less effect on protein
stability, reducing the half-life to 45 min. These data demon-
strate that the VN8 TADs cause protein destabilization to an
extent that is strikingly similar to their relative abilities to activate
transcription. Importantly, the increased stability of the mutant
activator (33M), relative to its wild-type counterpart (33), also
demonstrates that tandem reiteration of sequences per se is not
responsible for this effect.
Lastly, we asked whether the VN8 TADs direct protein
ubiquitylation. To do this, we asked whether GAL4–VN8 de-
rivatives could become covalently linked to polyhistidine-tagged
human Ub (His–Ub; ref. 2), as shown in Fig. 4. Under these
conditions, the GAL4 DBD alone displayed little if any ubiq-
uitylation (lane 12). Addition of one copy of VN8 did not result
in any increase in ubiquitylation (lane 14). Addition of three and
six copies of the VN8 module did, however, result in a significant
increase in ubiquitylation: GAL4–33VN8 (lane 16) displayed a
significant level of monoubiquitylation, as well as a smaller level
of higher molecular weight species, and GAL4–63VN8 (lane
18) displayed at least three prominent high molecular weight Ub
conjugates (arrowed; compare lanes 17 and 18), as well as a
smear of larger Ub conjugates. In contrast to the wild-type
33VN8 protein (lane 16), the mutant 33M derivative (lane 20)
failed to show any detectable level of ubiquitylation in this assay.
Thus, as with steady-state protein accumulation and protein
stability, there appears to be a direct relationship between
transcriptional potency and ubiquitylation status, with potent
transcriptional activators being more heavily ubiquitylated than
weaker activators.
These results clearly demonstrate that VN8 modules signal
Ub-mediated proteolysis in a manner that reflects their ability to
activate transcription. The tight overlap of these two activities
within a set of small, well-defined protein sequences reveals that
the relationship between activation domain and degron function
is intimate. Together with the results of our previous studies of
Myc, these data suggest that, in some cases, activation domains
and degrons are identical elements. We refer to sequences with
dual degronyactivation domain function by the acronym DAD
(destruction and activation domain).
Degrons from Yeast Cyclins Cln2 and Cln3 Activate Transcription. The
realization that activation domains can signal proteolysis
prompted us to ask the complementary question: Can degrons
activate transcription? For this purpose, we chose degrons from
the yeast cyclins Cln2 (18) and Cln3 (19). We fused the Cln2 and
Fig. 3. The ability of VN8 modules to signal proteolysis correlates with their
ability to activate transcription. (A) Steady-state levels of the GAL4-VN8
activators. Human HeLa cells were transiently transfected with expression
constructs encoding the indicated GAL4-fusion proteins. After transfection,
cells were either untreated (2LLnL) or treated with the proteasome inhibitor
LLnL (1LLnL). Total proteins were prepared and HA-tagged GAL4-fusion
proteins revealed by SDSyPAGE and immunoblotting analysis. (B) Stability of
GAL4–VN8 activators. GAL4-VN8 proteins were transiently expressed in HeLa
cells and their stabilities were determined by pulse–chase analysis as described
in Materials and Methods.
Fig. 4. The ubiquitylation status of GAL4-VN8 proteins is directly related to
transcriptional potency. HeLa cells were transfected with expression con-
structs encoding the indicated GAL4-fusion proteins, either alone (odd-
numbered lanes) or with an expression construct encoding polyhistidine-
tagged human Ub (His-Ub; even-numbered lanes). After transfection, cells
were treated with LLnL to allow the unstable GAL4-derivatives to accumulate.
Cellular proteins were harvested as described in Materials and Methods, and
HA-tagged GAL4-fusion proteins present in the total lysate (lanes 1–10) or the
nickel-affinity-purified material (lanes 11–20) were revealed by SDSyPAGE
and immunoblotting. The arrows indicate the position of His-Ub-GAL4–
63VN8 conjugates (lane 18).
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Cln3 degrons to the GAL4 DBD (as illustrated in Fig. 5A) and
examined their ability to activate an appropriate reporter con-
struct. We originally examined transcriptional activation by these
proteins in human HeLa cells and found that GAL4-Cln2 and
GAL4-Cln3 did not activate transcription (data not shown). We
also found, however, that the Cln2 and Cln3 degrons did not
destabilize the GAL4 DBD in HeLa cells (data not shown),
suggesting that these elements could not function in a human cell
environment. We therefore tested the activity of these GAL4-
fusion proteins in yeast cells, where the Cln2 and Cln3 degrons
can signal protein instability (18, 19). Results of this analysis are
presented in Fig. 5 B and C.
The yeast reporter strain we used in these experiments (HF7c;
ref. 21) carries two GAL-responsive reporters that allow GAL4-
fusion protein activity to be measured as either growth of yeast
in the presence of 3AT or as b-galactosidase activity. By both
criteria, the Cln2 and Cln3 degrons activate transcription. Al-
though the GAL4 DBD alone did not support yeast growth in the
presence of 2 mM 3AT, the GAL4–Cln2 and GAL4–Cln3 fusion
proteins supported yeast growth under these conditions (Fig.
5B). In addition, the GAL4–Cln2 and –Cln3 proteins activated
b-galactosidase synthesis to levels 5–6 times higher than that of
the GAL4 DBD alone (Fig. 5C). This level of activation was
considerably less than that seen with GAL4–Myc; this difference
is consistent with the fact that the Cln2 and Cln3 degrons are also
less effective at destabilizing GAL4 than the Myc DAD (data not
shown).
The normal role of Cln3 is to activate the transcription factors
SBF and MBF in late G1 phase of the cell cycle (38). Because of
our finding that the GAL4–Cln3 fusion activated transcription,
we were concerned that this could reflect a natural role of Cln3;
that is, perhaps Cln3 becomes part of the SBFyMBF DNA
complex and activates transcription directly. If this were so, it
would invalidate our assumption that the C-terminal domain of
Cln3 has evolved as a degron, rather than as a TAD. However,
we were able to identify mutant alleles of CLN3 that lacked the
ability to activate transcription as part of a GAL4 fusion, and yet
complemented a cln1 cln2 cln3 deletion (data not shown). Thus,
it appears that the normal role of Cln3 does not involve direct
transcriptional activation.
The experiments presented in Fig. 5 demonstrate that the
Cln2 and Cln3 degrons can activate transcription. The finding
that these degrons can activate transcription provides further,
compelling evidence for an intimate functional relationship
between TADs and degrons. It is curious to note that, unlike
the other DADs we have discussed, the Cln2 and Cln3 degrons
are not enriched in acidic amino acid residues. These se-
quences do, however, contain a large number of serine and
threonine residues and have been shown to be phosphorylated
(39, 40). In the case of Cln2, this phosphorylation is a
prerequisite for degron function (41), and this is likely true for
Cln3 as well (42). Perhaps the negative charge provided by
phosphorylation of these sequences mimics the environment
provided by an acidic activation domain. Similarly, perhaps
some acidic activation domains have degron function because
they mimic the environment provided by a phosphorylated
degron.
What Is the Significance of Overlapping Activation Domains and
Degrons? Our data reveal that two very different events—
transcriptional activation and Ub-mediated proteolysis—have
converged on a set of sequences capable of functioning in both
processes. The dual function of these DADs raises the question
of why transcriptional activation and proteolysis can be sig-
naled by a common element. One possibility is that cells have
evolved a machinery to destroy potent transcriptional activa-
tors; in this case, recognition of TADs by the ubiquitylation
machinery would provide an efficient means to target these
proteins for destruction. Such regulation could be important
for rapid reprogramming of transcriptional patterns, to limit
activation by any one single activator, or to prevent an
accumulation of excess activator that could lead to ‘‘squelch-
ing’’ of the basal machinery.
Considering our observation that degrons can activate tran-
scription, however, another possibility is that the overlap of
TADs and degrons reflects a functional link between transcrip-
tional activation and Ub-mediated proteolysis. Perhaps there is
a common cellular machinery that participates in both processes.
Indeed, there are many observations that support such a sce-
nario. For example, two subunits of the proteasome, Sug1 and
Sug2, interact genetically (43, 44) and biochemically (45) with
transcriptional activation domains. Sug1 also interacts with a
subunit of the basal transcription factor TFIIH (46). In addition,
the yeast Ub-protein ligase RSP5, and its human homolog
hPRF1, have coactivator function in vivo (47), directly interact
with TADs in vitro (48), and can ubiquitylate the largest subunit
of RNA polymerase II (49). Finally, we note that histones are
ubiquitylated and that their ubiquitylation status correlates with
transcriptional activity (e.g., ref. 50). Perhaps, therefore, some
activators can stimulate transcription by recruiting components
Fig. 5. The Cln2 and Cln3 degrons activate transcription in yeast. (A) Struc-
ture of the GAL4–Cln2 and –Cln3 activators. (B) Activation of His3p expression.
The indicated GAL4-fusion proteins were expressed in yeast strain HF7c, and
their ability to activate transcription was scored by yeast growth in the
presence of 3AT. Yeast were grown either in media containing histidine
(nonselective; Left) or media lacking histidine and containing 2 mM 3AT
(selective media; Right). (C) Activation of b-galactosidase (b-gal) expression.
Liquid cultures of HF7c cells carrying an empty expression vector (2) or vectors
expressing the indicated GAL4–fusion proteins were assayed for b-gal expres-
sion as described in Materials and Methods. Relative b-gal activity is expressed
relative to b-gal activity directed by the GAL4 DBD alone (D), which is set at 1.
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of the Ub-proteasome pathway that subsequently modify his-
tones, basal factors, and ultimately the activators themselves.
In conclusion, our data demonstrate that some activation
domains have a second function—the ability to signal Ub-
mediated proteolysis. The surprising overlap of two very differ-
ent processes suggests that many transcriptional activators are
destroyed because of their ability to activate transcription and
implies that a common targeting mechanism underlies the
destruction of transcriptional activators.
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